Pay in 4 interest-free payments of $7.23 Learn more
Ships within 48 hours · Estimated delivery Nov 7 - Nov 12
Alternative PBM Models: Pass-Through Pricing, GPO Disruption, and Market Challengers The Pass-Through PBM Model The alternative PBM category encompasses a range of business models that share a common claim: full pass-through of manufacturer rebates to plan sponsors, transparent pharmacy reimbursement equal to actual ingredient cost plus a disclosed dispensing fee, and no spread pricing
Suits all skin types
But a powerful medication is only one part of the equation
Theres no evidence to suggest that drinking Diet Coke may be to blame
Top GLP-1 Legal & Regulatory Concerns for Investors Miranda Schmalfuhs In this part of his Pharmaceutical Executive video interview, Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses the top legal and regulatory concerns for investors considering when financing companies developing or marketing GLP-1 drugs
The intracellular ROS level was initially investigated by the 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA) fluorescent probe
US$ 28.83
US$ 28.23
US$ 20.61
US$ 20.30
US$ 29.36
US$ 27.37
US$ 23.96
